9/17/2013 8:07:36 AM
Regado Biosciences (NASDAQ: RGDO) will now have the chance to prove that the two-pronged anticoagulant it pitched at its IPO roadshow is all it’s cracked up to be. The Basking Ridge, NJ-based biotech has officially enrolled the first patient in a massive late-stage clinical trial for its lead drug, REG-1. Regado expects to enroll a total of 13,200 patients at 500 sites around the world and complete the trial in 2015.
Help employers find you! Check out all the jobs and post your resume.
comments powered by